Suchergebnisse - "Pozniak, Anton"

PubPharm (30)

1

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa : modelling to inform treatment guidelines

enthalten in: The lancet. HIV | 2020

von Phillips, A. | Bansi-Matharu, L. | Venter, F. | +22

CommentIn: Lancet HIV. 2020 Mar;7(3):e154-e155. - PMID 32035042

2

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate : a pooled analysis of 26 clinical trials

enthalten in: AIDS (London, England) | 2019

von Gupta, S. | Post, F. | Arribas, J. | +21

3

Level of agreement between frequently used cardiovascular risk calculators in people living with HIV

enthalten in: HIV medicine | 2019

von Dhillon, S. | Sabin, C. | Alagaratnam, J. | +72

4

Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of tuberculosis : an observational cohort study

enthalten in: The Lancet. Infectious diseases | 2019

von Whitworth, H. | Badhan, A. | Boakye, A. | +27

CommentIn: Lancet Infect Dis. 2019 Feb;19(2):121-122. - PMID 30655048

5

Patient-Reported Outcomes in First-Line Antiretroviral Therapy : Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2018

von George, E. | Bucciardini, R. | Richert, L. | +14

6

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2018

von Ammassari, A. | Stöhr, W. | Antinori, A. | +10

7

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa : a modelling study

enthalten in: The lancet. HIV | 2018

von Phillips, A. | Cambiano, V. | Nakagawa, F. | +48

CommentIn: Lancet HIV. 2018 Mar;5(3):e112-e113. - PMID 29174085

8

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490) : a randomised, double-blind, multicentre, phase 3, non-inferiority trial

enthalten in: Lancet (London, England) | 2017

von Sax, P. | Pozniak, A. | Montes, M. | +13

CommentIn: Lancet. 2017 Nov 4;390(10107):2019-2021. - PMID 28867498

9

Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine : A Substudy of the NEAT001/ANRS143 Trial

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2017

von Winston, A. | Stöhr, W. | Antinori, A. | +13

10

Comparison of efavirenz and protease inhibitor based combination antiretroviral therapy regimens in treatment-naïve people living with HIV with baseline resistance

enthalten in: AIDS (London, England) | 2016

von Lim, C. | McFaul, K. | Kabagambe, S. | +6